{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:42:34Z","timestamp":1779277354567,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/bf03345702","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T11:04:41Z","timestamp":1395486281000},"page":"134-138","source":"Crossref","is-referenced-by-count":8,"title":["Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: Results of one-year follow-up"],"prefix":"10.1007","volume":"32","author":[{"given":"C.","family":"Regalbuto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Marturano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Latina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pezzino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,22]]},"reference":[{"key":"BF03345702_CR1","first-page":"624","volume":"21","author":"S Hertz","year":"1942","unstructured":"Hertz S, Roberts A. Application of radioactive iodine in therapy of Graves\u2019 disease. J Clin Invest 1942, 21: 624 (abstract).","journal-title":"J Clin Invest"},{"key":"BF03345702_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/thy.1997.7.163","volume":"7","author":"CT Sawin","year":"1997","unstructured":"Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid 1997, 7: 163\u201376.","journal-title":"Thyroid"},{"key":"BF03345702_CR3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1210\/jc.2003-031223","volume":"89","author":"CH Read Jr","year":"2004","unstructured":"Read CH Jr, Tansey M Jr, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves\u2019 patients. J Clin Endocrinol Metab 2004, 89: 4229\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","volume":"280","author":"E Ron","year":"1998","unstructured":"Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998, 280: 347\u201355.","journal-title":"JAMA"},{"key":"BF03345702_CR5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1055\/s-2003-41807","volume":"35","author":"N G\u00f3mez-Arnaiz","year":"2003","unstructured":"G\u00f3mez-Arnaiz N, Andia E, Gum\u00e0 A, Ab\u00f3s R, Soler J, G\u00f3mez JM. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves\u2019 disease hyperthyroidism. Horm Metab Res 2003, 35: 492\u20137.","journal-title":"Horm Metab Res"},{"key":"BF03345702_CR6","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/00006231-200411000-00003","volume":"25","author":"MF Erdogan","year":"2004","unstructured":"Erdogan MF, K\u00fc\u00e7\u00fck NO, Anil C, et al. Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenomas. Nucl Med Commun 2004, 25: 1083\u20137.","journal-title":"Nucl Med Commun"},{"key":"BF03345702_CR7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2265.2004.02152.x","volume":"61","author":"S Metso","year":"2004","unstructured":"Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol 2004, 61: 641\u20138.","journal-title":"Clin Endocrinol"},{"key":"BF03345702_CR8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","volume":"88","author":"WD Leslie","year":"2003","unstructured":"Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 2003, 88: 978\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.1991.tb01738.x","volume":"34","author":"JA Franklyn","year":"1991","unstructured":"Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991, 34: 71\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03345702_CR10","first-page":"411","volume":"32","author":"RA Nordyke","year":"1991","unstructured":"Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves\u2019 disease. J Nucl Med 1991, 32: 411\u20136.","journal-title":"J Nucl Med"},{"key":"BF03345702_CR11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2265.1988.tb03683.x","volume":"28","author":"AB Watson","year":"1988","unstructured":"Watson AB, Brownlie BE, Frampton CM, Turner JG, Rogers TG. Outcome following standardized 185 MBq dose 131I therapy for Graves\u2019 disease. Clin Endocrinol (Oxf) 1988, 28: 487\u201396.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03345702_CR12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1995.tb02039.x","volume":"43","author":"AE Jarl\u00f8v","year":"1995","unstructured":"Jarl\u00f8v AE, Heged\u00fcs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin Endocrinol (Oxf) 1995, 43: 325\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03345702_CR13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJM198408163110702","volume":"311","author":"V Sridama","year":"1984","unstructured":"Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves\u2019 disease. N Engl J Med 1984, 311: 426\u201332.","journal-title":"N Engl J Med"},{"key":"BF03345702_CR14","first-page":"1073","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander EK, Reed Larsen P. High dose (131)I therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab 2002, 87: 1073\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR15","first-page":"3488","volume":"86","author":"VA Andrade","year":"2001","unstructured":"Andrade VA, Gross JL, Maia AL. The effect of methimazole pre-treatment on the efficacy of radioactive iodine therapy in Graves\u2019 hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001, 86: 3488\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.0.1410117","volume":"141","author":"B Catargi","year":"1999","unstructured":"Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of Graves\u2019 disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol 1999, 141: 117\u201321.","journal-title":"Eur J Endocrinol"},{"key":"BF03345702_CR17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2265.2005.02218.x","volume":"62","author":"C Ceccarelli","year":"2005","unstructured":"Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years\u2019 retrospective study. Clin Endocrinol (Oxf) 2005, 62: 331\u20135.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03345702_CR18","unstructured":"Dottorini ME, Inglese E, Salvatori M, Signori A, Squatrito S, Vitti P. Il trattamento radiometabolico dell\u2019ipertiroidismo. 2005 http:\/\/www.societaitalianadiendocrinologia.it\/file\/lg_tratt_rad_ipertiro.pdf"},{"key":"BF03345702_CR19","volume-title":"\u201cS\u201d absorbed dose per unit cumulated activity for selected radionuclides and organs, MIRD Pamphlet No. 11","author":"W Snyder","year":"1975","unstructured":"Snyder W, Ford M, Warner G, Watson S. \u201cS\u201d absorbed dose per unit cumulated activity for selected radionuclides and organs, MIRD Pamphlet No. 11, Society of Nuclear Medicine, New York, NY 1975."},{"key":"BF03345702_CR20","first-page":"1206","volume":"287","author":"J Brunn","year":"1983","unstructured":"Brunn J, Block U, Ruf J, Bos I, Kunze WP, Scriba PC. Volumetrie derschilddrusenlappen mittels real-time-sonographie. Dtsch Med J 1983, 287: 1206\u20137.","journal-title":"Dtsch Med J"},{"key":"BF03345702_CR21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1210\/jc.2002-021801","volume":"88","author":"JE Kalinyak","year":"2003","unstructured":"Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves\u2019 hyperthyroidism? J Clin Endocrinol Metab 2003, 88: 975\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2362.1995.tb01547.x","volume":"25","author":"H Peters","year":"1995","unstructured":"Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves\u2019 hyperthyroidism: standar vs. calculated 131-iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995, 25: 186\u201393.","journal-title":"Eur J Clin Invest"},{"key":"BF03345702_CR23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00010","volume":"139","author":"L Chiovato","year":"2003","unstructured":"Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Inter Med 2003, 139: 346\u201351.","journal-title":"Ann Inter Med"},{"key":"BF03345702_CR24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2265.1991.tb03523.x","volume":"35","author":"AD Toft","year":"1991","unstructured":"FarrarJJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol (Oxf) 1991, 35: 207\u201312.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03345702_CR25","first-page":"3611","volume":"86","author":"A Allahabadia","year":"2001","unstructured":"Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism \u2014 Prognostic factors for outcome. J Clin Endocrinol Metab 2001, 86: 3611\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1385\/ENDO:25:1:55","volume":"25","author":"C Erem","year":"2004","unstructured":"Erem C, Kandemir N, Hacihasanoglu A, Ers\u00f6z HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine 2004, 25: 55\u201360.","journal-title":"Endocrine"},{"key":"BF03345702_CR27","first-page":"40","volume":"83","author":"L Chiovato","year":"1998","unstructured":"Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves\u2019 patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998, 83: 40\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF03348615","volume":"13","author":"C Marcocci","year":"1990","unstructured":"Marcocci C, Gianchecchi D, Masini I, et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves\u2019 hyperthyroidism. J Endocrinol Invest 1990, 13: 513\u201320.","journal-title":"J Endocrinol Invest"},{"key":"BF03345702_CR29","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1210\/jc.2007-0879","volume":"92","author":"V Markovic","year":"2007","unstructured":"Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves\u2019 disease. J Clin Endocrinol Metab 2007, 92: 3547\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR30","first-page":"1229","volume":"84","author":"O Sabri","year":"1999","unstructured":"Sabri O, Zimny M, Schulz G, et al. Success rate of radioiodine therapy in Graves\u2019 disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999, 84: 1229\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.39114.670150.BE","volume":"334","author":"MA Walter","year":"2007","unstructured":"Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007, 334: 514\u20137.","journal-title":"BMJ"},{"key":"BF03345702_CR32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1210\/jcem.83.2.4538","volume":"83","author":"RE Imseis","year":"1998","unstructured":"Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998, 83: 685\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR33","first-page":"1038","volume":"85","author":"A Allahabadia","year":"2000","unstructured":"Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 2000, 85: 1038\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345702_CR34","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/BF03344157","volume":"29","author":"B Tarantini","year":"2006","unstructured":"Tarantini B, Ciuoli C, Di Cairano G, et al. Effectiveness of radioiodine (131I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Invest 2006, 29: 594\u20138.","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03345702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03345702\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03345702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T10:25:56Z","timestamp":1558520756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03345702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["BF03345702"],"URL":"https:\/\/doi.org\/10.1007\/bf03345702","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}